LungLife AI Valuation

Is LLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

UK£1.50

Fair Value

96.3% undervalued

Number of Analysts

Below Fair Value: LLA (£0.06) is trading below our estimate of fair value (£1.5)

Significantly Below Fair Value: LLA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LLA?

Key metric: As LLA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LLA. This is calculated by dividing LLA's market cap by their current revenue.
What is LLA's PS Ratio?
PS Ratio	26.2x
Sales	US$29.00k
Market Cap	US$760.83k

LLA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LLA's PS Ratio compare to its peers?

The above table shows the PS ratio for LLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14x
OPTI OptiBiotix Health	27.1x	n/a	UK£15.4m
ONC Oncimmune Holdings	8.4x	105.1%	UK£10.2m
APTA Aptamer Group	9.2x	n/a	UK£7.9m
GENF Genflow Biosciences	11.4x	n/a	UK£6.8m
LLA LungLife AI	26.2x	17.0%	UK£613.2k

Price-To-Sales vs Peers: LLA is expensive based on its Price-To-Sales Ratio (26.2x) compared to the peer average (14x).

Price to Sales Ratio vs Industry

How does LLA's PS Ratio compare vs other companies in the GB Biotechs Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.8x	3.5%	US$1.46b
TRX Tissue Regenix Group	1.6x	15.1%	US$52.09m
VRCI Verici Dx	2.6x	78.8%	US$11.27m
0HMP Bellerophon Therapeutics	0.09x	n/a	US$489.31k

No more companies available in this PS range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LLA is expensive based on its Price-To-Sales Ratio (26.2x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is LLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LLA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	26.2x
Fair PS Ratio	1.3x

Price-To-Sales vs Fair Ratio: LLA is expensive based on its Price-To-Sales Ratio (26.2x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target

Consensus Narrative from 1 Analyst

UK£4.70

Fair Value

98.8% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 01:34
End of Day Share Price	2025/02/07 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LungLife AI, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Adam Barker	Goodbody Stockbrokers
Zoe Karamanoli	Goodbody Stockbrokers
Andrew Whitney	Investec Bank plc (UK)